A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children

Abstract In this clinical trial, the safety and effectiveness of Lactobacillus paracasei N1115 (LP N1115) were investigated as a potential probiotic to enhance gut development in young children born by caesarean section. Infants and young children between the ages of 6 months and 3 years were admini...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shijie Wang, Yiping Xun, Grace J. Ahern, Lili Feng, Dong Zhang, Yuling Xue, Reynolds Paul Ross, Andrea M. Doolan, Catherine Stanton, Hong Zhu
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	caesarean section fecal microbiota Lactobacillus paracasei N1115 probiotic short‐chain fatty acid Nutrition. Foods and food supply TX341-641
Acceso en línea:	https://doaj.org/article/45391579f401486195328ef6c6f61917
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:45391579f401486195328ef6c6f61917
record_format	dspace
spelling	oai:doaj.org-article:45391579f401486195328ef6c6f619172021-11-04T13:06:43ZA randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children2048-717710.1002/fsn3.2533https://doaj.org/article/45391579f401486195328ef6c6f619172021-11-01T00:00:00Zhttps://doi.org/10.1002/fsn3.2533https://doaj.org/toc/2048-7177Abstract In this clinical trial, the safety and effectiveness of Lactobacillus paracasei N1115 (LP N1115) were investigated as a potential probiotic to enhance gut development in young children born by caesarean section. Infants and young children between the ages of 6 months and 3 years were administered with a probiotic consisting of LP N1115 strain (n = 30) or placebo supplement (n = 30) over an 8 weeks intervention. And the stool consistency, bowel habits, salivary cortisol, fecal microbiota, and short‐chain fatty acid metabolism were investigated. Efficacy data were obtained from 58 participants who completed the study. Overall, the placebo functioned similarly to LP N1115 group in relation to stool consistency, gastrointestinal symptoms, salivary cortisol, and short‐chain fatty acids. However, the scoring data relating to the 6–18 months subgroup receiving LP N1115 remained stable over 8 weeks in comparison to placebo. Analysis of the fecal microbiota using 16S rRNA amplicon sequencing revealed that the phyla Firmicutes represented 62% of the microbial relative abundance in the feces of the subjects during the intervening period. No significant changes in alpha‐ or beta‐diversity were noted between the placebo and LP N1115 groups overtime and at each time point. Differential abundance analysis indicated an increase in Lactobacillus in LP N1115 group at weeks 4 (p < .05) and 8 (p < .05) in comparison to the placebo group. These results suggest that probiotic supplementation with LP N1115 was well tolerated by the young children and subtle changes in the microbiome were noted throughout the intervention period.Shijie WangYiping XunGrace J. AhernLili FengDong ZhangYuling XueReynolds Paul RossAndrea M. DoolanCatherine StantonHong ZhuWileyarticlecaesarean sectionfecal microbiotaLactobacillus paracasei N1115probioticshort‐chain fatty acidNutrition. Foods and food supplyTX341-641ENFood Science & Nutrition, Vol 9, Iss 11, Pp 6020-6030 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	caesarean section fecal microbiota Lactobacillus paracasei N1115 probiotic short‐chain fatty acid Nutrition. Foods and food supply TX341-641
spellingShingle	caesarean section fecal microbiota Lactobacillus paracasei N1115 probiotic short‐chain fatty acid Nutrition. Foods and food supply TX341-641 Shijie Wang Yiping Xun Grace J. Ahern Lili Feng Dong Zhang Yuling Xue Reynolds Paul Ross Andrea M. Doolan Catherine Stanton Hong Zhu A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
description	Abstract In this clinical trial, the safety and effectiveness of Lactobacillus paracasei N1115 (LP N1115) were investigated as a potential probiotic to enhance gut development in young children born by caesarean section. Infants and young children between the ages of 6 months and 3 years were administered with a probiotic consisting of LP N1115 strain (n = 30) or placebo supplement (n = 30) over an 8 weeks intervention. And the stool consistency, bowel habits, salivary cortisol, fecal microbiota, and short‐chain fatty acid metabolism were investigated. Efficacy data were obtained from 58 participants who completed the study. Overall, the placebo functioned similarly to LP N1115 group in relation to stool consistency, gastrointestinal symptoms, salivary cortisol, and short‐chain fatty acids. However, the scoring data relating to the 6–18 months subgroup receiving LP N1115 remained stable over 8 weeks in comparison to placebo. Analysis of the fecal microbiota using 16S rRNA amplicon sequencing revealed that the phyla Firmicutes represented 62% of the microbial relative abundance in the feces of the subjects during the intervening period. No significant changes in alpha‐ or beta‐diversity were noted between the placebo and LP N1115 groups overtime and at each time point. Differential abundance analysis indicated an increase in Lactobacillus in LP N1115 group at weeks 4 (p < .05) and 8 (p < .05) in comparison to the placebo group. These results suggest that probiotic supplementation with LP N1115 was well tolerated by the young children and subtle changes in the microbiome were noted throughout the intervention period.
format	article
author	Shijie Wang Yiping Xun Grace J. Ahern Lili Feng Dong Zhang Yuling Xue Reynolds Paul Ross Andrea M. Doolan Catherine Stanton Hong Zhu
author_facet	Shijie Wang Yiping Xun Grace J. Ahern Lili Feng Dong Zhang Yuling Xue Reynolds Paul Ross Andrea M. Doolan Catherine Stanton Hong Zhu
author_sort	Shijie Wang
title	A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
title_short	A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
title_full	A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
title_fullStr	A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
title_full_unstemmed	A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children
title_sort	randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of lactobacillus paracasei n1115 in gut development of young children
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/45391579f401486195328ef6c6f61917
work_keys_str_mv	AT shijiewang arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT yipingxun arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT gracejahern arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT lilifeng arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT dongzhang arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT yulingxue arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT reynoldspaulross arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT andreamdoolan arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT catherinestanton arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT hongzhu arandomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT shijiewang randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT yipingxun randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT gracejahern randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT lilifeng randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT dongzhang randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT yulingxue randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT reynoldspaulross randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT andreamdoolan randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT catherinestanton randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren AT hongzhu randomizeddoubleblindparallelplacebocontrolledstudytoinvestigatetheefficacyoflactobacillusparacasein1115ingutdevelopmentofyoungchildren
_version_	1718444896425082880

A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children

Ejemplares similares